The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
Open accessAbstract
Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development.Significance: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 2×
“In the phase III registration study of ipilimumab and nivolumab versus sunitinib, patients with intermediate- to poor-risk disease had superior survival and response compared with favorable-risk patients, setting this regimen apart from others (4).”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citationMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Self-citationKeren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183 · cited 1×
“Moreover, important spatial or coinfiltration patterns can be missed when relying fully on genomics and protein cytometry (28, 83).”
BackgroundCD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J. H., Zanotelli, V. R. T., Silina, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,004
Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 994
Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968
Self-citationTargeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · cited 1×
“Recently, PBRM1 was discovered to confer resistance to T cell–induced apoptosis, and deletion in a B16F10 melanoma mouse model increases susceptibility to anti–PD-1 and anti-CTLA4 (63).”
BackgroundTracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J. I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.057 · Cited by 829
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
Hakimi, A. A., Reznik, E., Lee, C.-H., Creighton, C. J., Brannon, A. R., Luna, A., Aksoy, B. A., Liu, E. M., Shen, R., Lee, W., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.004 · Cited by 798
Self-citationThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.032 · Cited by 734
Self-citationWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T., O’Brien, T., Lopez, J. I., Watkins, T. B. K., Nicol, D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.043 · Cited by 655
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 639
Tertiary lymphoid structures in cancer and beyond
Dieu-Nosjean, M.-C., Goc, J., Giraldo, N. A., Sautès-Fridman, C., & Fridman, W. H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.006 · Cited by 617
Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Giraldo, N. A., Becht, E., Pagès, F., Skliris, G., Verkarre, V., Vano, Y., Mejean, A., Saint-Aubert, N., Lacroix, L., Natario, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2926 · Cited by 507
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Beroukhim, R., Brunet, J.-P., Di Napoli, A., Mertz, K. D., Seeley, A., Pires, M. M., Linhart, D., Worrell, R. A., Moch, H., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0146 · Cited by 412
Siska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
Giraldo, N. A., Becht, E., Vano, Y., Petitprez, F., Lacroix, L., Validire, P., Sanchez-Salas, R., Ingels, A., Oudard, S., Moatti, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2848 · Cited by 375
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Beuselinck, B., Job, S., Becht, E., Karadimou, A., Verkarre, V., Couchy, G., Giraldo, N., Rioux-Leclercq, N., Molinié, V., Sibony, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1128 · Cited by 315
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Brooks, S. A., Brannon, A. R., Parker, J. S., Fisher, J. C., Sen, O., Kattan, M. W., Hakimi, A. A., Hsieh, J. J., Choueiri, T. K., Tamboli, P., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.035 · Cited by 301
Self-citationHakimi, A. A., Voss, M. H., Kuo, F., Sanchez, A., Liu, M., Nixon, B. G., Vuong, L., Ostrovnaya, I., Chen, Y.-B., Reuter, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0957 · Cited by 258
Self-citationGenetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
Linehan, W. M. (2012) · Genome Research · doi:10.1101/gr.131110.111 · Cited by 243
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Liu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions
Amici, S. A., Young, N. A., Narvaez-Miranda, J., Jablonski, K. A., Arcos, J., Rosas, L., Papenfuss, T. L., Torrelles, J. B., Jarjour, W. N., & Guerau-de-Arellano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01593 · Cited by 204
Hsieh, J. J., Le, V. H., Oyama, T., Ricketts, C. J., Ho, T. H., & Cheng, E. H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2549 · Cited by 182
Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment
Varn, F. S., Wang, Y., Mullins, D. W., Fiering, S., & Cheng, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2490 · Cited by 169
Wang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 168
Gao, W., Li, W., Xiao, T., Liu, X. S., & Kaelin, W. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619726114 · Cited by 167
PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes
Locke, L. W., Mayo, M. W., Yoo, A. D., Williams, M. B., & Berr, S. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.022 · Cited by 136
Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Hawkins, R. E., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., Vynnychenko, I. O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4500 · Cited by 120
Aboud, O. A., Habib, S. L., Trott, J. F., Stewart, B. J., Liang, S., Chaudhari, A. J., Sutcliffe-Goulden, J., & Weiss, R. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0930 · Cited by 118
Matsushita, H., Sato, Y., Karasaki, T., Nakagawa, T., Kume, H., Ogawa, S., Homma, Y., & Kakimi, K. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0225 · Cited by 98
Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study
Iv, M., Samghabadi, P., Holdsworth, S. J., Gentles, A. J., Rezaii, P. G., Harsh, G. R., Li, G., Thomas, R. P., Moseley, M. E., Daldrup-Link, H. E., et al. (2018) · Radiology · doi:10.1148/radiol.2018181204 · Cited by 84
McDermott, D. F., Choueiri, T. K., Motzer, R. J., Aren, O. R., George, S., Powles, T. B., Donskov, F. N., Harrison, M. R., Cid, J. R. R., Ishii, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4513 · Cited by 82
Powles, T. B., Sarwar, N., Stockdale, A. D., Sarker, S., Boleti, E., Protheroe, A. S., Jones, R. J., Chowdhury, S., Peters, J., Oades, G. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1197 · Cited by 81
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
de Velasco, G., Miao, D., Voss, M. H., Hakimi, A. A., Hsieh, J. J.-D., Tannir, N. M., Tamboli, P., Appleman, L. J., Rathmell, W. K., Allen, E. M. V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0110 · Cited by 78
Self-citationWang, Q. J., Hanada, K., Robbins, P. F., Li, Y. F., & Yang, J. C.-H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0588 · Cited by 76
Tannir, N. M., Frontera, O. A., Hammers, H. J., Carducci, M. A., McDermott, D. F., Salman, P., Escudier, B. J., Beuselinck, B., Amin, A., Porta, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.547 · Cited by 69
Yin, Q., Hung, S., Wang, L., Lin, W., Fielding, J. R., Rathmell, W. K., Khandani, A. H., Woods, M. E., Milowsky, M. I., Brooks, S. A., et al. (2017) · Scientific Reports · doi:10.1038/srep43356 · Cited by 67
de Velasco, G., Culhane, A. C., Fay, A. P., Hakimi, A. A., Voss, M. H., Tannir, N. M., Tamboli, P., Appleman, L. J., Joaquim Bellmunt, B., Rathmell, W. K., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0078 · Cited by 66
Self-citationTK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Zizzari, I. G., Napoletano, C., Botticelli, A., Caponnetto, S., Calabrò, F., Gelibter, A. J., Rughetti, A., Ruscito, I., Rahimi, H., Rossi, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0594 · Cited by 64
Verbiest, A., Couchy, G., Job, S., Caruana, L., Lerut, E., Oyen, R., de Reyniès, A., Tosco, L., Joniau, S., Poppel, H. V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.042 · Cited by 56
Diab, A. K., Hurwitz, M. E., Cho, D. C., Papadimitrakopoulou, V. A., Curti, B. D., Tykodi, S. S., Puzanov, I. J., Ibrahim, N. K., Tolaney, S. M., Tripathy, D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3006 · Cited by 56
Verbiest, A., Couchy, G., Job, S., Zucman‐Rossi, J., Caruana, L., Lerut, E., Oyen, R., de Reyniès, A., Laguerre, B., Rioux-Leclercq, N. C., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.017 · Cited by 55
The Role of CD38 in Fcγ Receptor (FcγR)-mediated Phagocytosis in Murine Macrophages
Kang, J., Park, K., Kim, J.-J., Jo, E., Han, M., & Kim, U. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.329003 · Cited by 45
Rini, B. I., Motzer, R. J., Powles, T. B., McDermott, D. F., Escudier, B. J., Donskov, F. N., Hawkins, R. E., Sergio Bracarda, A., Bedke, J., Giorgi, U. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4512 · Cited by 32
Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.
Giannakis, M., Li, H., Jin, C., Gopal, S., Desai, K. D., Horak, C. E., Wind‐Rotolo, M., Allen, E. M. V., Clish, C. B., Hodi, F. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3036 · Cited by 26
Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B. C., Iliopoulos, O., Mier, J. W., Patel, M. R., Meric‐Bernstam, F., DeMichele, A. M., Voss, M. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.603 · Cited by 24
Self-citation
Cited by
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
Borcherding, N., Vishwakarma, A., Voigt, A. P., Bellizzi, A., Kaplan, J., Nepple, K., Salem, A. K., Jenkins, R. W., Zakharia, Y., & Zhang, W. (2021) · Communications Biology · doi:10.1038/s42003-020-01625-6 · Cited by 364
Cancer-associated fibroblasts: overview, progress, challenges, and directions
Ping, Q., Yan, R., Cheng, X., Wang, W., Zhong, Y., Hou, Z., Shi, Y., Wang, C., & Li, R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00318-4 · Cited by 285
The role of hyaluronan in renal cell carcinoma
Jin, C., & Zong, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127828 · Cited by 17
Metadata
- Authors
- Vuong, L., Kotecha, R. R., Voss, M. H., & Hakimi, A. A.
- Venue
- Cancer Discovery
- Published
- 2019-10-01
- Volume
- 9
- Issue
- 10
- Pages
- 1349-1357
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2974687396
- Cited by
- 436
- References
- 76
- FWCI
- 25.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.